Published 3 days ago • loading... • Updated 3 days ago

FDA to miss approval deadline for Kalvista drug due to ‘resource constraints’

Summary by healthcaredive.com

A “heavy workload” and “limited resources” have left the agency unable to meet a June 17 deadline to approve a therapy Kalvista has been developing for hereditary angioedema.

2 Articles

All

Left

Center

Right

healthcaredive.com

Reposted by

biopharmadive.com

Center

FDA to miss approval deadline for Kalvista drug due to ‘resource constraints’

A “heavy workload” and “limited resources” have left the agency unable to meet a June 17 deadline to approve a therapy Kalvista has been developing for hereditary angioedema.

3 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right